Founded by Medicxi with Georgia Tech and UMass scientists, supported by US $30M investment from Medicxi Developing advanced, long-lasting therapies for dermatological diseases through radical new transepidermal delivery of proprietary siRNAs Led by dermatology veteran Thibaud Portal as CEO with a Scientific Advisory Board chaired by Nobel Prize Laureate, Craig Mello Boston, Massachusetts, March 16th, […]
Turku, Finland – March 15, 2023 – DelSiTech Ltd, a Finnish drug delivery and drug development company, today announces that it has been awarded a grant from the Bill & Melinda Gates Foundation to develop long-acting injectable formulations ensuring the slow release of human immunodeficiency virus (HIV) vaccine. This funding marks the third grant awarded from the Bill […]
MacroGenics adds up to four ADC programs MacroGenics may combine both its proprietary antibody and bispecific DART® technologies with Synaffix’s linker-payload technologies Expanded collaboration includes up to $2.2 billion in total potential payments plus tiered royalties on net sales AMSTERDAM, NETHERLANDS, 14 March 2023, Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage platform […]
First-in-class SK channel inhibition proof of mechanism achieved First new approach to treating Atrial Fibrillation for 20 years Copenhagen, Denmark – Acesion Pharma (“Acesion”), the biotech pioneering first-in-class novel therapies for Atrial Fibrillation (“AF”), the most common cardiac arrhythmia, today announced positive data from its Phase 2 trial of AP30663, a first-in-class SK ion channel […]
Financing co-led by Sunstone Life Science Ventures and Sound Bioventures with participation from Industrifonden, Innovestor’s Life Science Fund and P53 Invest Discovery of a novel mechanism with the potential to prevent the death of neurons in neurodegenerative diseases First-in-Class, lead drug candidate advances into clinical development in a Phase 1b study Aarhus, Denmark March 14th, […]
